← Back to Clinical Trials
Recruiting NCT03224312

Chongqing Primary Aldosteronism Study

Trial Parameters

Condition Primary Aldosteronism
Sponsor Chongqing Medical University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,500
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2016-10-01
Completion 2027-12-31
Interventions
no intervention

Brief Summary

We intends to conduct a series of original clinical research about PA, and establish a large cohort of PA and essential hypertension patients with long-term follow-up of cardiovascular events, renal end points etc. We will establish a large sample of blood, urine, adrenal tissue of the subjects, and the genomics,metabonomics, proteomics database, to explore the mechanism of the PA and target organ damage, risk factors, diagnostic methods and biomarkers.

Eligibility Criteria

Inclusion Criteria: 1. hypertensive patients who completed ARR screening and necessary further tests; 2. Voluntary to sign the informed consent. Exclusion Criteria: 1. patients with severe cardiac, hepatic or renal dysfunction; 2. suspicious or confirmed other types of secondary hypertension, including Cushing's syndrome, pheochromocytoma and renal artery stenosis et al.

Related Trials